Editorial

Short-course adjuvant trastuzumab will increase cure rates in patients with human epidermal growth factor receptor 2-positive breast cancer

Bookmark and Share
Raymond Pierre Abratt

Abstract


-

Author's affiliations

Raymond Pierre Abratt, Head of Clinical Governance, Independent Clinical Oncology Network, Cape Town, South Africa; Emeritus Professor of Radiation Oncology, Faculty of Health Sciences, University of Cape Town, South Africa

Full Text

PDF (63KB)

Keywords

Trastuzumab; Breast cancer; Cure rates

Cite this article

South African Medical Journal 2017;107(8):654-655. DOI:10.7196/SAMJ.2017.v107i8.12673

Article History

Date submitted: 2017-07-28
Date published: 2017-07-28

Article Views

Abstract views: 2051
Full text views: 932

Comments on this article

*Read our policy for posting comments here